0.05Open0.05Pre Close0 Volume71 Open Interest1.00Strike Price0.00Turnover5182.37%IV45.56%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0927Delta0.1815Gamma34.90Leverage Ratio-2.0277Theta0.0000Rho-3.23Eff Leverage0.0000Vega
Scilex Holding Stock Discussion
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido® Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region
Scilex Holding Company (Nasdaq: SCLX) has entered a Memorandum of Understanding (MOU) with ACEA Therapeutics for collaboration on ZTlido®, a lidocaine topical system for neuropathic pain relief. The a...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
▪️The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the Internation...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
Scilex Holding Company (Nasdaq: SCLX) has entered into a commitment letter with Perigrove and Graf Holdings for a $100 million 5-year term financing with royalty-based payments. The funds will be used primarily to repay an existing $85 million senior secured loan from Oramed Pharmaceuticals...
No comment yet